What's in CEL-SCI Corporation's pipeline?

CEL-SCI Corporation has 1 drugs in our index: 1 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with CEL-SCI Corporation's portfolio?

Top competitors by shared drug class: Haffkine Bio-Pharmaceutical Corporation Ltd., Immodulon Therapeutics Ltd.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/cel-sci-corporation.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-14 · How we verify

CEL-SCI Corporation — Portfolio Competitive Intelligence Brief

CEL-SCI Corporation pipeline: 1 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
LI	LI	marketed	Cancer immunotherapy vaccine		Oncology

Therapeutic area mix

Oncology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Haffkine Bio-Pharmaceutical Corporation Ltd. · 1 shared drug class
Immodulon Therapeutics Ltd · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for CEL-SCI Corporation:

Cite this brief

Drug Landscape (2026). CEL-SCI Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/cel-sci-corporation. Accessed 2026-05-14.